Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

Dong W. Kim; Kwangzoo Chung; Weon K. Chung; Sun H. Bae; Dong O. Shin; Seongeon Hong; Sung H. Park; Sung Yong Park; Chae Seon Hong; Young K. Lim; Dongho Shin; Se B. Lee; Hyun ho Lee; Jiwon Sung; Myonggeun Yoon

doi:10.1186/1748-717X-9-109

Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

Dong W. Kim, Kwangzoo Chung, Weon K. Chung, Sun H. Bae, Dong O. Shin, Seongeon Hong, Sung H. Park, Sung Yong Park, Chae Seon Hong, Young K. Lim, Dongho Shin, Se B. Lee, Hyun ho Lee, Jiwon Sung, Myonggeun Yoon

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 10⁴ person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

Original language	English
Article number	109
Journal	Radiation Oncology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1186/1748-717X-9-109
Publication status	Published - 2014 May 8

Bibliographical note

Funding Information:
This work was supported by the General Researcher Program (NRF-2012R1A1A2003174); the Nuclear Safety Research Program (Grant No. 1305033) through the Korea Radiation Safety Foundation (KORSAFe) and the Nuclear Safety and Security Commission (NSSC); the Radiation Safety Program (2011–31115); and Radiation Technology Development Program (2013M2A2A4027117), Republic of Korea.

Keywords

EAR
ERR
HCC
IMRT
LAR
OED
Radiophotoluminescence
Tomotherapy
VMAT

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1748-717X-9-109

Cite this

Kim, D. W., Chung, K., Chung, W. K., Bae, S. H., Shin, D. O., Hong, S., Park, S. H., Park, S. Y., Hong, C. S., Lim, Y. K., Shin, D., Lee, S. B., Lee, H. H., Sung, J., & Yoon, M. (2014). Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma. Radiation Oncology, 9(1), Article 109. https://doi.org/10.1186/1748-717X-9-109

@article{dbba7d698b1e4e3e9a598ae35b811712,

title = "Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma",

abstract = "Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.",

keywords = "EAR, ERR, HCC, IMRT, LAR, OED, Radiophotoluminescence, Tomotherapy, VMAT",

author = "Kim, {Dong W.} and Kwangzoo Chung and Chung, {Weon K.} and Bae, {Sun H.} and Shin, {Dong O.} and Seongeon Hong and Park, {Sung H.} and Park, {Sung Yong} and Hong, {Chae Seon} and Lim, {Young K.} and Dongho Shin and Lee, {Se B.} and Lee, {Hyun ho} and Jiwon Sung and Myonggeun Yoon",

note = "Funding Information: This work was supported by the General Researcher Program (NRF-2012R1A1A2003174); the Nuclear Safety Research Program (Grant No. 1305033) through the Korea Radiation Safety Foundation (KORSAFe) and the Nuclear Safety and Security Commission (NSSC); the Radiation Safety Program (2011–31115); and Radiation Technology Development Program (2013M2A2A4027117), Republic of Korea.",

year = "2014",

month = may,

day = "8",

doi = "10.1186/1748-717X-9-109",

language = "English",

volume = "9",

journal = "Radiation Oncology",

issn = "1748-717X",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

AU - Kim, Dong W.

AU - Chung, Kwangzoo

AU - Chung, Weon K.

AU - Bae, Sun H.

AU - Shin, Dong O.

AU - Hong, Seongeon

AU - Park, Sung H.

AU - Park, Sung Yong

AU - Hong, Chae Seon

AU - Lim, Young K.

AU - Shin, Dongho

AU - Lee, Se B.

AU - Lee, Hyun ho

AU - Sung, Jiwon

AU - Yoon, Myonggeun

N1 - Funding Information: This work was supported by the General Researcher Program (NRF-2012R1A1A2003174); the Nuclear Safety Research Program (Grant No. 1305033) through the Korea Radiation Safety Foundation (KORSAFe) and the Nuclear Safety and Security Commission (NSSC); the Radiation Safety Program (2011–31115); and Radiation Technology Development Program (2013M2A2A4027117), Republic of Korea.

PY - 2014/5/8

Y1 - 2014/5/8

N2 - Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

AB - Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.

KW - EAR

KW - ERR

KW - HCC

KW - IMRT

KW - LAR

KW - OED

KW - Radiophotoluminescence

KW - Tomotherapy

KW - VMAT

UR - http://www.scopus.com/inward/record.url?scp=84901246509&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-9-109

DO - 10.1186/1748-717X-9-109

M3 - Article

C2 - 24886163

AN - SCOPUS:84901246509

SN - 1748-717X

VL - 9

JO - Radiation Oncology

JF - Radiation Oncology

IS - 1

M1 - 109

ER -

Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this